Genitourinary Cancer,Prostate Cancer Daro Exhibited a Lower Projected Rate of Discontinuation/Progression vs. Enza and APA in nmCRPC Sep 21, 2023
Genitourinary Cancer,Prostate Cancer DARO + ADT + Docetaxel Improved Efficacy In North American Patients With mHSPC Sep 21, 2023
Prostate Cancer DARO+ADT+Docetaxel Attained Rapid, Durable, And Deep PSA Responses In mHSPC Patients Sep 20, 2023
